Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polysomnography in drug development

B Dietrich1

  • 1L.A.B. GmbH, Neu Ulm, Germany.

Journal of Clinical Pharmacology
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Polysomnography is crucial for drug development, assessing sleep effects. This review highlights its importance, requirements, and limitations for new drug approvals, especially for non-hypnotics.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.

ESMO open·2021
Same author

3-Dimensional JEG-3 choriocarcinoma cell organoids as a model for trophoblast expansion and differentiation.

Placenta·2021
Same author

Preclinical assessment of a new recombinant ADAMTS-13 drug product (BAX930) for the treatment of thrombotic thrombocytopenic purpura.

Journal of thrombosis and haemostasis : JTH·2016
Same author

A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas.

European journal of cancer (Oxford, England : 1990)·2016
Same author

[Hippocampal stroke].

Der Nervenarzt·2015
Same author

Malfunction of endothelial progenitor cells and endothelial function in patients with Fabry disease.

Journal of stem cells & regenerative medicine·2014
Same journal

AI is Excellent at the Discovery and Identification of Unrecognized Scientific Knowledge but There Is No Evidence That AI Can Create New Scientific Knowledge.

Journal of clinical pharmacology·2026
Same journal

Ketamine Dosing Across Clinical Indications: A Narrative Review Organized by Proposed NMDA-Related Mechanisms.

Journal of clinical pharmacology·2026
Same journal

Flip-Flop Pharmacokinetics in Pregnancy and the Future of Obstetric Pharmacology.

Journal of clinical pharmacology·2026
Same journal

Correction to "A Phase 1 Study Evaluating the Pharmacokinetics and Safety of Avacopan in Participants With End-Stage Kidney Disease on Hemodialysis".

Journal of clinical pharmacology·2026
Same journal

Street Pharmacology: The Mechanistic Basis of Clinical Pharmacology Underlying the Microdosing Method of Buprenorphine-Naloxone With a Focus on the Unhoused Population.

Journal of clinical pharmacology·2026
Same journal

Ontology-Enhanced Deep Learning for Mechanistic Prediction of Drug-Drug Interactions: A Clinically Interpretable Framework.

Journal of clinical pharmacology·2026
See all related articles

Area of Science:

  • Pharmacology
  • Sleep Medicine
  • Drug Development

Background:

  • Polysomnography (PSG) is vital for evaluating drug impacts on sleep.
  • It is essential for hypnotic drug approval but often overlooked for other drug classes.
  • Understanding PSG's role is key to comprehensive drug safety assessment.

Purpose of the Study:

  • To review the requirements for qualified polysomnography in drug development.
  • To discuss the strengths and weaknesses of polysomnography.
  • To emphasize the importance of polysomnography in the drug development process.

Main Methods:

  • Literature review of polysomnography applications in drug development.
  • Analysis of polysomnography's utility for assessing drug-induced sleep disturbances.

Related Experiment Videos

  • Discussion of methodological requirements and limitations.

    • Main Results:

    • Polysomnography effectively detects both positive and negative drug effects on sleep.
    • The method's application is inconsistent, particularly for non-hypnotic drugs.
    • Qualified polysomnography requires specific standards for reliable data.

    Conclusions:

    • Polysomnography is an indispensable tool in drug development for sleep-related assessments.
    • Standardized polysomnography protocols are needed to ensure data quality and drug safety.
    • Increased utilization of polysomnography can improve the understanding of drug effects on sleep.